Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rinaldi

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Circulation. Cardiovascular Interventions|June 10, 2015
Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registryUsman Baber, Roxana Mehran, Ajay J Kirtane, et al.
JACC. Cardiovascular Interventions|January 31, 2021
Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DESKatherine H Chau, Ajay J Kirtane, Rachel M Easterwood, et al.
Circulation. Cardiovascular Interventions|January 21, 2026
Atrial Secondary Mitral Regurgitation Outcomes Following Mitral Transcatheter Edge-to-Edge Repair: Results From the EXPANDed StudiesMark J Ricciardi, Gagan Singh, Jason H Rogers, et al.
Circulation. Cardiovascular Interventions|December 21, 2018
Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting StentsAkiko Maehara, Gary S Mintz, Bernhard Witzenbichler, et al.
Circulation. Cardiovascular Interventions|March 9, 2016
Response to Letter Regarding Article, "Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study"Giora Weisz, Nathaniel R Smilowitz, Ajay J Kirtane, et al.
JACC. Cardiovascular Interventions|January 8, 2016
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)Ajay J Kirtane, Puja B Parikh, Thomas D Stuckey, et al.
Journal of the American College of Cardiology|February 26, 2021
3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart FailureMichael J Mack, JoAnn Lindenfeld, William T Abraham, et al.
The American Journal of Cardiology|September 4, 2019
Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study)Björn Redfors, Shmuel Chen, Ori Ben-Yehuda, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 2007
Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammationGerald S Horan, Susan Wood, Victor Ona, et al.
Circulation. Cardiovascular Interventions|February 15, 2017
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)Jennifer Yu, Roxana Mehran, Usman Baber, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Circulation. Cardiovascular Interventions|June 10, 2015
Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registryUsman Baber, Roxana Mehran, Ajay J Kirtane, et al.
JACC. Cardiovascular Interventions|January 31, 2021
Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DESKatherine H Chau, Ajay J Kirtane, Rachel M Easterwood, et al.
Circulation. Cardiovascular Interventions|January 21, 2026
Atrial Secondary Mitral Regurgitation Outcomes Following Mitral Transcatheter Edge-to-Edge Repair: Results From the EXPANDed StudiesMark J Ricciardi, Gagan Singh, Jason H Rogers, et al.
Circulation. Cardiovascular Interventions|December 21, 2018
Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting StentsAkiko Maehara, Gary S Mintz, Bernhard Witzenbichler, et al.
Circulation. Cardiovascular Interventions|March 9, 2016
Response to Letter Regarding Article, "Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study"Giora Weisz, Nathaniel R Smilowitz, Ajay J Kirtane, et al.
JACC. Cardiovascular Interventions|January 8, 2016
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)Ajay J Kirtane, Puja B Parikh, Thomas D Stuckey, et al.
Journal of the American College of Cardiology|February 26, 2021
3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart FailureMichael J Mack, JoAnn Lindenfeld, William T Abraham, et al.
The American Journal of Cardiology|September 4, 2019
Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study)Björn Redfors, Shmuel Chen, Ori Ben-Yehuda, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 2007
Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammationGerald S Horan, Susan Wood, Victor Ona, et al.
Circulation. Cardiovascular Interventions|February 15, 2017
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)Jennifer Yu, Roxana Mehran, Usman Baber, et al.
Pageof 18